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ecal  microbiota  transplantation  (FMT)  represents  the  most
romising  free-antibiotic  therapy  in  the  management  of
atients  with  infection  by  Clostridium  difﬁcile,  recurrent
r  refractory  to  treatment  with  antibiotics.  FMT’s  superior-
ty  over  conventional  treatment  has  been  proven  in  multiple
eries  of  cases  and  recently  in  experimental  prospective  ran-
omized  clinical  trials  with  a  resolution  of  the  infection  in
ver  90%  of  patients.1
FMT  occurs  when  intestinal  microorganisms  are  infused
ith  a  suspension  from  a  healthy  donor  into  a  sick  patient  for
he  purposes  of  restoring  altered  microbiota.  The  ﬁrst  known
escription  of  the  use  of  human  feces  as  a  therapeutic  agent
omes  from  China.  During  the  IV  century,  Ge  Hong  prescribed
-  in  the  emergency  medicine  pocket  book  --  the  intake  of
eces  for  different  diseases.  The  success  of  fecal  microbiota
ransplantation  in  modern  medicine  was  ﬁrst  described  by
iseman  et  al.  in  1958,  administrating  microbiota  in  enemas
o  patients  with  pseudomembranous  colitis.2,3
C.  difﬁcile  is  a  Gram-positive  spore-forming  bacteria  iso-
ated  in  1935  and  described  for  the  ﬁrst  time  as  a  cause  of
iarrhea  and  pseudomembranous  colitis  in  a  patient  in  1978.
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nder the CC BY-NC-ND license (http://creativecommons.org/licenses/bn  the  last  three  decades  we  have  witnessed  the  increase
n  the  incidence  and  severity  of  infectious  proﬁles  by  C.
ifﬁcile,  making  it  a  serious  health  issue,  increasing  mor-
idity  and  mortality  in  hospitalized  patients  as  well  as  in
utpatients.  The  incidence  of  infection  by  C.  difﬁcile  in  the
ommunity  has  increased  5.3  times  from  1991  to  2005  and  in
hese  outpatients  the  disease  occurs  in  young  adults  without
omorbidities  who  lack  traditional  risk  factors  like  the  expo-
ure  to  antibiotics  and  recent  hospitalization.  This  suggests
ew  risk  factors  and  new  forms  of  transmission.3,4
One  of  the  factors  which  has  contributed  to  the  increase
n  the  number  of  cases  of  infection  by  C.  difﬁcile  is  the  pres-
nce  of  a  new,  more  virulent,  quinolone-resistant  strain,
hich  produces  16  times  more  toxin  A  and  23  times  more
oxin  B,  in  addition  to  a  third  toxin,  which  has  enterotoxi-
enic  activity  in  vitro.5 Moreover,  this  new  strain  produces
ore  spores,  conditioning  a  greater  pollution  in  the  envi-
onment,  thereby  increasing  the  risk  of  spreading.  This
pidemic  strain  is  associated  with  a  higher  incidence  of  com-
licated  cases  and  a  higher  mortality  rate.  Initially  identiﬁed
y  a  restriction  endonuclease  analysis  and  denominated  as  BI
1980),  it  is  currently  referred  to  as  Type  1  (NAP1)  by  pulsed
elds  analysis  or  ribotype  027  by  ribotypiﬁcation.  This  NAP1
train  has  spread  widely  in  the  US;  nevertheless,  very  few
linics  are  aware  of  its  presence  due  to  its  characteristics.1,4
Current  recommendations  to  decide  on  a  treatment  for
atients  with  infection  by  C.  difﬁcile  are  based  on  clinical
everity.  Patients  with  mild  infections  may  be  treated  with
etronidazole  500  mg,  administered  orally  3  times  a  day,  or
ancomycin  125  mg,  administered  orally  4 times  a  day  for
niversidad Autónoma de Nuevo León. This is an open access article
y-nc-nd/4.0/).
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10  days.  Severe  cases  are  treated  with  vancomycin  125  mg,
administered  orally  4  times  a  day  for  10  days.  Complicated
severe  cases  are  treated  with  a  combination  of  vancomycin
500  mg,  administered  orally  4  times  a  day,  plus  metronida-
zole  500  mg  IV  every  8  h  and  rectal  vancomycin  (vancomycin
500  mg  in  500  ml  of  saline  solution  in  enema)  4  times  a  day
in  case  of  the  presence  of  ileus.5
However,  one  of  the  challenging  aspects  in  the  man-
agement  of  patients  with  a  C.  difﬁcile  infection  is  the
recurrence  of  the  disease  after  a  successful  treatment.  It
is  considered  a  recurrence  when  symptoms  restart  within
the  ﬁrst  8  weeks  after  the  end  of  treatment.  Recurrence
rates  after  treatment  with  metronidazole  and  vancomycin
are  similar  (20.2%  and  18.4%,  respectively)6.  For  the  treat-
ment  of  recurrences,  we  recommend  the  same  treatment
that  was  used  during  the  initial  episode,  coupled  with  a
suspension  of  any  antibiotics  the  patient  may  be  taking  to
allow  the  restoration  of  the  intestinal  microﬂora.  If  the
new  episode  is  severe,  vancomycin  should  be  utilized.  Some
experts  recommend  giving  pulses  of  vancomycin  in  the  case
of  a  second  recurrence.  Other  antibiotics,  like  rifaximin  and
ﬁdaxomicin,  have  been  tested  in  cases  of  recurrence  and
obtained  variable  results  and,  overall,  a  greater  cost7,8. Nei-
ther  of  these  is  currently  recommended  for  recurring  cases.
In  the  context  of  treating  a  recurrent  C.  difﬁcile
infection,  we  are  confronted  with  a  grand  paradigm;  the
recurring  infection  is  secondary  to  a  disruption  of  the  colonic
microﬂora  started  by  the  antibiotic  therapy  and  perpetuated
by  metronidazole  or  vancomycin.  The  antibiotics  destroy
the  bacteria,  but  also  destroy  the  intestinal  microbiota,
which  is  vital  to  maintaining  health,  immunity  and  colonic
metabolism.  The  risk  of  recurrence  is  greater  in  patients
with  a  previous  recurrence,  increasing  by  20%  after  the  ﬁrst
episode,  up  to  40%  with  the  ﬁrst  recurrence  and  up  to  more
than  60%  after  2  recurrences4,9.
There  is  a  decrease  in  the  diversity  of  fecal  microbiota  in
patients  with  recurrent  diarrhea  due  to  a  C.  difﬁcile  infec-
tion.  This  decrease  can  be  observed,  for  the  most  part,  in
the  concentration  of  the  specie  Bacteroides  and  Fermicutes.
Because  of  this,  a  treatment  without  antibiotics,  preser-
ving  and  restoring  microbiotic  diversity,  can  represent  a  new
strategy  to  achieve  the  prevention  and  treatment  of  recur-
ring  C.  difﬁcile  infections10.  FMT  has  been  demonstrated  to
be  an  effective  alternative  in  the  treatment  of  refractory
C.  difﬁcile  infections,  and  is  the  most  radical  and  direct
method  to  change  the  composition  of  the  colon  microbiota2.
To  perform  a  FMT,  a  feces  sample  from  a  healthy  person
is  required.  In  our  hospital  we  performed  a  simple  ques-
tionnaire  looking  for  a  person  without  comorbidities,  with
an  adequate  BMI,  who  did  not  have  any  antecedent  of  pre-
vious  hospitalization  or  use  of  antibiotics  within  the  last  3
months.  We  performed  general  examinations  (blood  count,
blood  chemistry)  a  viral  proﬁle  (HBVAgs,  Antibodies  against
HCV  and  HIV),  a  coprological  is  conducted  as  well  as  a  single
stool  specimen  ova  and  parasite  examination  and  toxins  A
and  B  for  C.  difﬁcile  in  feces.
Upon  deciding  that  the  patient  with  a  C.  difﬁcile  infec-
tion  is  a  candidate  for  FMT,  the  use  of  antibiotics  was
suspended  for  48--72  h  and  a  nasojejunal  probe  was  placed
and  its  adequate  placement  veriﬁed  by  simple  X-rays.  One
day  before  the  transplant,  4  packets  of  Nulitely  (109.6  g
each)  were  administered,  each  one  diluted  in  4  L  of  water.193
n  the  day  of  the  transplant  a  fecal  material  sample  is
equested  from  the  donor  in  the  morning,  and  laboratory
ersonnel  homogenize  the  sample  in  a  saline  solution  and
lter  it,  obtaining  approximately  50  ml  of  microbiotic  solu-
ion.  The  FMT  is  administered  by  means  of  the  nasojejunal
robe.  In  case  it  does  not  advance  to  the  small  intestine,
n  endoscope  is  used  to  instill  the  FMT  directly  into  the
uodenum.  The  case  can  be  used  as  an  alternate  method
f  administering  a colonoscopy,  as  the  situation  warrants.
he  therapy  is  considered  to  be  effective  when  the  diarrhea
isappears  after  the  administration  of  the  FMT.
The  superiority  of  the  FMT  over  treatment  with  antibi-
tics  has  been  demonstrated  in  multiple  publications.  The
eries  of  cases  show  favorable  responses  in  more  than  90%
f  cases11. Recently,  a  controlled  randomized  study  was  per-
ormed,  comparing  the  effectiveness  of  FMT  (n  =  16)  against
reatment  with  antibiotics,  observing  the  resolution  of  the
isease  in  94%  of  cases  (3  patients  received  a  double  FMT
nfusion)12.  Now,  there  are  studies  that  show  its  utility  in
eriously  ill  patients  or  immunosuppressed  patients  with
ecurring  or  refracting  C.  difﬁcile  infections,  observing  a
ecovery  in  89%  (n  =  80).  In  our  center,  we  have  used  the
MT  in  refractory  as  well  as  recurring  cases.  For  the  most
art,  the  patients  are  hospitalized  and  suffering  from  multi-
le  comorbidities.  We  have  obtained  a  resolution  of  diarrhea
f  87%,  and  were  able  to  avoid  surgical  management  and
educe  morbi-mortality  in  these  patients.  Recently,  meth-
ds  have  been  developed  to  freeze  the  microbiota  for  the
MT  in  capsules  at  −80C◦ and  study  its  effects  in  cases  of
efractory  C.  difﬁcile  infections,  with  an  observed  effective-
ess  of  90%13. None  of  the  studies  have  reported  signiﬁcant
ide  effects.  Other  uses  that  the  FMT  has  been  used  for  have
een  in  patients  with  a C.  difﬁcile  infection  and  inﬂamma-
ory  bowel  disease  (IBD),  including  a  therapeutic  proposal  in
ases  of  refractory  IBD1.
By  what  has  been  documented,  we  can  conclude  that  the
MT  has  shown  its  usefulness  in  patients  with  a recurrent  or
efractory  C.  difﬁcile  infection,  and  as  a  medical  treatment
ven  for  patients  that  are  seriously  ill  or  with  some  degree
f  immunosuppression.  With  the  increase  in  the  incidence
nd  severity  of  C.  difﬁcile  infections,  the  FMT  has  a  very
mportant  role  to  play  in  the  combating  of  this  disease.  Our
xperience  underlines  the  fact  that  treatment  with  FMT  in
exico  is  a reality.  The  requirements  for  its  implementation
nd  the  technical  process  are  simple,  bringing  the  option  of
 cure  to  the  majority  of  patients  managed  with  this  therapy,
hich  is  free  of  antibiotics  and  serious  adverse  effects.
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